AGTI:NYE-Agiliti Inc (USD)

COMMON STOCK | Health Information Services | NYE

Last Closing Price

USD 16.33

Change

0.00 (0.00)%

Market Cap

USD 2.23B

Volume

0.21M

Avg Analyst Target

USD 24.63 (+50.80%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AGTI Stock Forecast & Price:
Based on the Agiliti Inc stock forecasts from 5 analysts, the average analyst target price for Agiliti Inc is USD 24.63 over the next 12 months. Agiliti Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Agiliti Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Agiliti Inc’s stock price was USD 16.33. Agiliti Inc’s stock price has changed by -6.42% over the past week, -1.69% over the past month and -14.81% over the last year.

About Agiliti Inc (AGTI:NYE)

Agiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. It offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of med ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VEEV Veeva Systems Inc Class A

N/A

USD25.90B 71.90 46.99
SGFY Signify Health Inc

N/A

USD8.55B 127.39 -20.25
DOCS Doximity Inc

N/A

USD5.94B 44.33 43.90
TDOC Teladoc Inc

N/A

USD4.73B N/A -0.59
EVH Evolent Health Inc

N/A

USD3.70B N/A 65.45
MPLN MultiPlan Corporation

N/A

USD1.91B 11.94 7.10
PHR Phreesia Inc

N/A

USD1.38B 2.91 -7.38
AMWL American Well Corp

N/A

USD1.02B N/A -1.62
CNVY Convey Holding Parent Inc

N/A

USD0.77B N/A 25.29
CSLT Castlight Health Inc

N/A

USD0.34B N/A N/A

ETFs Containing AGTI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.49% 75% C 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.49% 75% C 27% F
Trailing 12 Months  
Capital Gain -14.81% 73% C 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.81% 73% C 56% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.57% 55% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.57% 55% F 22% F
Risk Return Profile  
Volatility (Standard Deviation) 9.63% 100% A+ 81% B-
Risk Adjusted Return -5.90% 45% F 22% F
Market Capitalization 2.23B 58% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 50.67 50% F 10% F
Price/Book Ratio 2.50 58% F 31% F
Price / Cash Flow Ratio 10.59 50% F 34% F
EV/EBITDA 11.73 42% F 33% F
Management Effectiveness  
Return on Equity 5.00% 75% C 38% F
Return on Invested Capital 4.79% 75% C 47% F
Return on Assets 3.19% 75% C 58% F
Debt to Equity Ratio 129.08% 22% F 27% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 13.21 17% F 3% F
Short Percent 8.22% 33% F 32% F
Beta 1.01 25% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector